Alumis (ALMS) has drawn fresh attention after reporting positive topline Phase 3 ONWARD results for envudeucitinib in moderate to severe plaque psoriasis. All primary and secondary endpoints were met, ...
Alumis shares soar as the biotech firm’s envudeucitinib meets all primary and secondary endpoints in a Phase 3 trial. Here’s ...
Alumis (ALMS) has announced a public offering of 17.65M shares of common stock priced at $17.00 per share. This offering is ...
Alumis Inc. surged on Phase 3 psoriasis data for envudeucitinib. Click for this look at ALMS stock and why I am bullish on ...
Alumis (ALMS) stock surged after two Phase 3 trial for its lead drug, envudeucitinib, succeeded against plaque psoriasis.
Asianet Newsable on MSN
Why is ALMS stock rising today?
One Stocktwits user stated that now is a good time to buy the stock following the announcement of the trial results. Another ...
Alumis (ALMS) stock is soaring after the company announced positive trial results for its plaque psoriasis drug ...
Inquirer.net on MSN
LIST: Class suspensions on Jan. 8 due to bad weather
Several local government units in Bicol Region have suspended face-to-face classes on Jan. 8, Thursday, and either directed or advised schools to adopt ...
In the main salon of the collector Giorgio Taroni’s home on Italy’s Lake Como, a chestnut staircase curves around a nook ...
The group housing Trump’s controversial cost-cutting program is one of several tech teams that are recruiting.
Immune-mediated diseases specialist Alumis has announced positive top-line results from its Phase III ONWARD1 and ONWARD2 ...
Blending Amari's signature Thai warmth and contemporary style, the experience comes to life through thoughtful design and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback